QUEST DIAGNOSTICS Q1 FY26 earnings call DGX

Quest Diagnostics demonstrated strong performance across its core customer channels. The physician channel achieved high single-digit revenue growth, driven by clinical innovations, expanded health plan access, and growth in enterprise accounts. The hospital channel saw double-digit revenue growth, largely due to the successful collaborative lab solutions with Corewell Health. The consumer channel also experienced significant double-digit revenue growth from questhealth.com and strategic partnerships, empowering individuals with direct access to lab insights.

The company reported double-digit revenue growth in several key clinical areas, including brain health and cardiometabolic testing. Notably, the AD-Detect blood test for Alzheimer's disease more than doubled its revenue year-over-year in Q1 FY26, supported by a proprietary algorithm combining multiple biomarkers with high sensitivity and specificity. New guidelines from the American Heart Association recommending Lp(a) and ApoB testing also contributed to growth in the cardiometabolic portfolio. A research collaboration with City of Hope for the Haystack MRD test in solid tumor cancers was also announced.

Quest continues to focus on operational excellence through its Invigorate program, targeting 3% annual cost savings and productivity improvements. The company significantly expanded its deployment of AI and automation, boosting customer service agent productivity by 40% in Q1 by using AI to triage emails. Additionally, the Quest AI Companion, powered by Google Gemini, was rolled out to MyQuest app users, engaging approximately 350,000 patients to simplify complex biomarker data into plain language, fostering shared decision-making with clinicians.

Planning and design work for Project Nova, a multiyear initiative to transform order-to-cash processes and systems, is on track. The first wave of solutions is slated for implementation in the fall of 2027. This strategic investment is expected to incur a $0.25 EPS dilution for the full year, with over 60% of these expenses anticipated in the second half of FY26, reflecting the ramp-up of this significant modernization effort.

Quest Diagnostics is preparing for the PAMA data submission, which opens in May, and is advocating for the RESULTS Act to stabilize Medicare rates. Management expressed hope that broader participation in the PAMA survey by other hospital labs, which typically receive higher commercial rates, could lead to an increase in Medicare rates for 2027. The company also addressed the CMS CRUSH RFI, stating minimal exposure to the tests identified as driving increased Medicare spending and advocating for lab accreditation for complex testing.

The M&A funnel remains active, with a mix of health system outreach deals and potential independent lab acquisitions. Management noted that while Medicare reimbursement changes do not significantly alter hospitals' views on their outreach business, the increasing scrutiny from health plans regarding the higher rates paid to hospital labs compared to independent labs is a growing factor. Quest advocates for normalized reimbursement rates across all labs for outreach work to benefit employers and patients.